104 related articles for article (PubMed ID: 9182885)
1. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram.
Nyman U; Müssener A; Larsson E; Lorentzen J; Klareskog L
Clin Exp Immunol; 1997 Jun; 108(3):415-9. PubMed ID: 9182885
[TBL] [Abstract][Full Text] [Related]
2. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram.
Ross SE; Williams RO; Mason LJ; Mauri C; Marinova-Mutafchieva L; Malfait AM; Maini RN; Feldmann M
J Immunol; 1997 Dec; 159(12):6253-9. PubMed ID: 9550429
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.
Sekut L; Yarnall D; Stimpson SA; Noel LS; Bateman-Fite R; Clark RL; Brackeen MF; Menius JA; Connolly KM
Clin Exp Immunol; 1995 Apr; 100(1):126-32. PubMed ID: 7697910
[TBL] [Abstract][Full Text] [Related]
4. TNF-alpha dominates cytokine mRNA expression in lymphoid tissues of rats developing collagen- and oil-induced arthritis.
Müssener A; Klareskog L; Lorentzen JC; Kleinau S
Scand J Immunol; 1995 Jul; 42(1):128-34. PubMed ID: 7631134
[TBL] [Abstract][Full Text] [Related]
5. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
7. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
Kambayashi T; Jacob CO; Zhou D; Mazurek N; Fong M; Strassmann G
J Immunol; 1995 Nov; 155(10):4909-16. PubMed ID: 7594495
[TBL] [Abstract][Full Text] [Related]
8. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
[TBL] [Abstract][Full Text] [Related]
9. Effects of the phosphodiesterase IV inhibitor rolipram on Th1 and Th2 immune responses in mice.
Yamaki K; Li X; Uchida H; Alam AH; Hossain MA; Yanagisawa R; Takano H; Taneda S; Hayashi H; Mori Y; Yoshino S
J Pharm Pharmacol; 2004 Jul; 56(7):877-82. PubMed ID: 15233866
[TBL] [Abstract][Full Text] [Related]
10. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
Hughes B; Howat D; Lisle H; Holbrook M; James T; Gozzard N; Blease K; Hughes P; Kingaby R; Warrellow G; Alexander R; Head J; Boyd E; Eaton M; Perry M; Wales M; Smith B; Owens R; Catterall C; Lumb S; Russell A; Allen R; Merriman M; Bloxham D; Higgs G
Br J Pharmacol; 1996 Jul; 118(5):1183-91. PubMed ID: 8818342
[TBL] [Abstract][Full Text] [Related]
11. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
12. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
[TBL] [Abstract][Full Text] [Related]
13. Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram.
Buttini M; Mir A; Appel K; Wiederhold KH; Limonta S; Gebicke-Haerter PJ; Boddeke HW
Br J Pharmacol; 1997 Dec; 122(7):1483-9. PubMed ID: 9421299
[TBL] [Abstract][Full Text] [Related]
14. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
[TBL] [Abstract][Full Text] [Related]
15. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
Shafiee-Nick R; Pyne NJ; Furman BL
Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
[TBL] [Abstract][Full Text] [Related]
16. Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats.
Chi ZL; Hayasaka S; Zhang XY; Hayasaka Y; Cui HS
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2497-502. PubMed ID: 15277469
[TBL] [Abstract][Full Text] [Related]
17. Difference in preventive effects between the phosphodiesterase iv inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice.
Yamaki K; Li X; Hossain MA; Alam AH; Taneda S; Yanagisawa R; Takano H; Yoshino S
Immunol Invest; 2007; 36(2):131-45. PubMed ID: 17365015
[TBL] [Abstract][Full Text] [Related]
18. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
19. Altered Th1/Th2 balance associated with non-major histocompatibility complex genes in collagen-induced arthritis in resistant and non-resistant rat strains.
Müssener A; Lorentzen JC; Kleinau S; Klareskog L
Eur J Immunol; 1997 Mar; 27(3):695-9. PubMed ID: 9079811
[TBL] [Abstract][Full Text] [Related]
20. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis.
Foey AD; Field S; Ahmed S; Jain A; Feldmann M; Brennan FM; Williams R
Arthritis Res Ther; 2003; 5(6):R317-28. PubMed ID: 14680506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
